Cutaneous androgen metabolism: Basic research and clinical perspectives

Journal of Investigative Dermatology

Volumn 119, Issue 5, 2002, Pages 992-1007

  Chen, WenChieh ^a   Thiboutot, Diane ^b   Zouboulis, Christos C ^c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acne vulgaris; Androgen antagonists; Androgenetic alopecia; Androgens; Hirsutism

Indexed keywords

2 METHOXYESTRONE 3 O SULFAMATE; 3 O SULFAMATE ESTRONE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; 3ALPHA HYDROXYSTEROID DEHYDROGENASE; 4 [3 [3 [BIS(4 ISOBUTYLPHENYL)METHYLAMINO]BENZOYL] 1H INDOL 1 YL]BUTYRIC ACID; 8 CHLORO 1,2,3,4,4A,5,6,10B OCTAHYDRO 4 METHYLBENZO[F]QUINOLIN 3(2H) ONE; ANDROGEN; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTERONE DERIVATIVE; AROMATASE; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYANOKETONE; CYTOCHROME P450; DAIDZEIN; ENZYME INHIBITOR; EPRISTERIDE; ESTRADIOL DERIVATIVE; ESTRONE DERIVATIVE; GENISTEIN; GESTAGEN; GLUCURONIDE; ISOENZYME; ISOFLAVONOID; LIGNAN DERIVATIVE; MK 434; MK 963; N [2,2,2 TRIFLUORO 1 PHENYL 1 (TRIFLUOROMETHYL)ETHYL] 3 OXO 4 AZA 5ALPHA ANDROST 1 ENE 17BETA CARBOXAMIDE; NORETHISTERONE; NORGESTREL; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE; STERYL SULFATASE; TESTOSTERONE 17BETA DEHYDROGENASE; TRILOSTANE; TZP 4283; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ACNE VULGARIS; ALOPECIA; ANDROGEN BLOOD LEVEL; ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; CYTOPLASM; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME LOCALIZATION; FACE; HAIR FOLLICLE; HIRSUTISM; HUMAN; IMMUNOREACTIVITY; KERATINOCYTE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SEBACEOUS GLAND; SKIN; SKIN DEFECT;

EID: 0036446856     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2002.00613.x     Document Type: Review

References (251)

1. Sahokoski O, Irjala K, Huupponen R, Halonen K, Salminen E, Scheinin H: Hormonal effects of MPV-2213ad, a new selective aromatase inhibitor, in healthy male subjects. A phase I study. Br J Clin Pharmacol 45:141-146, 1998
2. Akamatsu H, Zouboulis CC, Orfanos CE: Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands. J Invest Dermatol 99:509-511, 1992
3. Alperin ES, Shapiro LJ: Characterization of point mutations in patients with X-linked ichthyosis. Effects on the structure and function of the steroid sulfatase protein. J Biol Chem 272:20756-20763, 1997
4. Ambadkar PM, Vyas DM: Effects of isoproterenol on hydroxysteroid dehydrogenases of preputial gland of male rats. Folia Histochem Cytochem 20:129-132, 1982
5. Anderson KM, Liao S: Selective retention of dihydrotestosterone by prostatic nuclei. Nature 219:277-279, 1968
6. Andersson S, Russell DW: Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci USA 87:3640-3644, 1990
7. Andersson S, Berman DM, Jenkins EP, Russell DW: Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 354:159-161, 1991
8. Andersson S, Moghrabi N: Physiology and molecular genetics of 17β-hydroxysteroid dehydrogenase. Steroids 62:143-147, 1997
9. Ando Y, Yamaguchi Y, Hamada K, Yoshikawa K, Itami S: Expression of mRNA for androgen receptor, 5 alpha-reductase and 17 beta-hydroxysteroid dehydrogenase in human dermal papilla cells. Br J Dermatol 141:840-845, 1999
10. Arlt W, Auchus RJ, Miller WL: Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta-hydroxysteroid dehydrogenase. J Biol Chem 276:16767-16771, 2001
11. Armanini D, Bonanni G, Palermo M: Reduction of serum testosterone in men by licorice. N Engl J Med 341:1158, 1999
12. Auchus RJ, Palmer JO, Carrell HL, Covey DF: Preparation of 14,15-secoestra-1,3,5(10)-trien-15-ynes, inhibitors of estradiol dehydrogenase. Steroids 53:77-96, 1989
13. Azziz R, Carmina E, Sawaya ME: Idiopathic hirsutism. Endocr Rev 21:347-362, 2000
14. Badri SN, Vanithakumari G, Malini T: Studies on methotrexate effects on testicular steroidogenesis in rats. Endocrinol Res 26:247-262, 2000
15. Baillie AH, Calman KC, Milne JA: Histochemical distribution of hydroxysteroid dehydrogenases in human skin. Br J Dermatol 77:610-616, 1965
16. Baillie AH, Thomson J, Milne JA: The distribution of hydroxysteroid dehydrogenase in human sebaceous glands. Br J Dermatol 78:451-457, 1966
17. Bartsch G, Rittmaster RS, Klocker H: Dihydrotestosterone and the concept of 5 alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 37:367-380, 2000
18. Bartsch W, Klein H, Sturenburg HJ, Voigt KD: Metabolism of androgens in human benign prostatic hyperplasia: Aromatase and its inhibition. J Steroid Biochem 27:557-564, 1987
19. Basler E, Grompe M, Parenti G, Yates J, Ballabio A: Identification of point mutations in the steroid sulfatase gene of three patients with X-linked ichthyosis. Am J Hum Gen 50:483-491, 1992
20. Baston E, Palusczak A, Hartmann RW: 6-Substituted 1H-quinolin-2-ones and 2-methoxy-quinolines: Synthesis and evaluation as inhibitors of steroid 5 alpha-reductases types 1 and 2. Eur J Med Chem 35:931-940, 2000
21. Bayne CW, Ross M, Donnelly F, Habib FK: The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. J Urol 164:876-881, 2000
22. Bayne EK, Flanagan J, Einstein M, et al: Immunohistochemical localization of types 1 and 2 5 alpha-reductase in human scalp. Br J Dermatol 141:481-491, 1999
23. Billich A, Nussbaumer P, Lehr P: Stimulation of MCF-7 breast cancer cell proliferation by estrone sulfate and dehydroepiandrosterone sulfate: Inhibition by novel non-steroidal steroid sulfatase inhibitors. J Steroid Biochem Mol Biol 73:225-235, 2000
24. Bingham KD, Shaw DA: The metabolism of testosterone by human male scalp skin. J Endocrinol 57:111-121, 1973
25. Biswas MG: Russell DW: Expression cloning and characterization of oxidative 17beta- and 3alpha-hydroxysteroid dehydrogenases from rat and human prostate. J Biol Chem 272:15959-15966, 1997
26. Blomquist CH: Kinetic analysis of enzymic activities: Prediction of multiple forms of 17 beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 55:515-524, 1995
27. Blomquist CH, Lindemann NJ, Hakanson EY: Inhibition of 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) activities of human placenta by steroids and non-steroidal hormone agonists and antagonists. Steroids 43:571-586, 1984
28. Blomquist CH, Lindemann NJ, Hakanson EY: Inactivation of soluble 17 beta-hydroxysteroid dehydrogenase of human placenta by fatty acids. J Steroid Biochem 23:357-363, 1985
29. Boivin RP, Luu-The V, Lachance R, Labrie F, Poirier D: Structure-activity relationships of 17alpha-derivatives of estradiol as inhibitors of steroid sulfatase. J Med Chem 43:4465-4478, 2000
30. Bonifas JM, Epstein EH Jr: Detection of carriers for X-linked ichthyosis by Southern blot analysis and identification of one family with a de novo mutation. J Invest Dermatol 95:16-19, 1990
31. Brenner S, Matz H: Improvement in androgenetic alopecia in 53-76-year old men using oral finasteride. Int J Dermatol 38:928-930, 1999
32. Bruchovsky N, Wilson JD: The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 243:2012-2021, 1968
33. Bulun SE: Aromatase deficiency and estrogen resistance: From molecular genetics to clinic. Semin Reprod Med 18:31-39, 2000
34. Bulun SE, Noble LS, Takayama K, et al: Endocrine disorders associated with inappropriately high aromatase expression. J Steroid Biochem Mol Biol 61:133-139, 1997
35. Carmina E, Lobo RA: Evidence for increased androsterone metabolism in some normoandrogenic women with acne. J Clin Endocrinol Metab 76:1111-1114, 1993
36. Carmina E, Stanczyk FZ, Matteri RK, Lobo RA: Serum androsterone conjugates differentiate between acne and hirsutism in hyperandrogenic women. Fertil Steril 55:872-876, 1991
37. Carmina E, Gentzschein E, Stanczyk FZ, Lobo RA: Substrate dependency of C19 conjugates in hirsute hyperandrogenic women and the influence of adrenal androgen. Hum Reprod 10:299-303, 1995a
38. Carmina E, Stanczyk FZ, Gentzchein E, Lobo RA: Time-dependent changes in serum 3 alpha-androstanediol glucuronide correlate with hirsutism scores after ovarian suppression. Gynecol Endocrinol 9:215-220, 1995b
39. Caspi EY, Hechter OM: Corticosteroid metabolism in liver. III. Isolation of additional cortisone metabolites. Arch Biochem Biophys 52:478-483, 1954
40. Caspi EY, Levy H, Hechter OM: Cortisone metabolism in liver. II. Isolation of certain cortisone metabolites. Arch Biochem Biophys 45:169-182, 1953
41. Chen W, Zouboulis CC, Orfanos CE: The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 193:177-184, 1996
42. Chen W, Zouboulis CC, Fritsch M, et al: Evidence of heterogeneity and quantitative differences of the type 1 5alpha-reductase expression in cultured human skin cells - Evidence of its presence in melanocytes. J Invest Dermatol 110:84-89, 1998a
43. Chen W, Zouboulis CC, Fritsch M, Kodelja V, Orfanos CE: Heterogeneity and quantitative differences of type 1 5 alpha-reductase expression in cultured skin epithelial cells. Dermatology 196:51-52, 1998b
44. Chetrite GS, Pasqualini JR: The selective estrogen enzyme modulator (SEEM) in breast cancer. J Steroid Biochem Mol Biol 76:95-104, 2001
45. Chetrite GS, Ebert C, Wright F, Philippe JC, Pasqualini JR: Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines. J Steroid Biochem Mol Biol 68:51-56, 1999
46. Ciobanu LC, Boivin RP, Luu-The V, Labrie F, Poirier D: Potent inhibition of steroid sulfatase activity by 3-O-sulfamate 17 alpha-benzyl(or 4′-tert-butylbenzyl)estra-1,3,5(10)-trienes: Combination of two substituents at positions C3 and C17alpha of estradiol. J Med Chem 42:2280-2286, 1999
47. Cooke GM: Differential effects of trilostane and cyanoketone on the 3 beta-hydroxysteroid dehydrogenase-isomerase reactions in androgen and 16-androstene biosynthetic pathways in the pig testis. J Steroid Biochem Mol Biol 58:95-101, 1996
48. Courchay G, Boyera N, Bernard BA, Mahe Y: Messenger RNA expression of steroidogenesis enzyme subtypes in the human pilosebaceous unit. Skin Pharmacol 9:169-176, 1996
49. Crovato F, Moretti G, Bertamino R: 17β-hydroxysteroid dehydrogenases in hair follicles of normal and bald scalp: A histochemical study. J Invest Dermatol 60:126-133, 1973
50. Dawber RP, Sinclair RD: Hirsuties. Clin Dermatol 19:189-199, 2001
51. Deplewski D, Rosenfield RL: Role of hormones in pilosebaceous unit development. Endocr Rev 21:363-92, 2000
52. Dijkstra AC, Goos CM, Cunliffe WJ, Sultan C, Vermorken AJ: Is increased 5 alpha-reductase activity a primary phenomenon in androgen-dependent skin disorders. J Invest Dermatol 89:87-92, 1987
53. Drake L, Hordinsky M, Fiedler V, et al: The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol 41:550-554, 1999
54. Dufort I, Soucy P, Labrie F, Luu-The V: Molecular cloning of human type 3 3alpha-hydroxysteroid dehydrogenase that differs from 20 alpha-hydroxysteroid dehydrogeanse by seven amino acids. Biochem Biophys Res Commun 228:474-479, 1996
55. Dufort I, Labrie F, Luu-The V: Human types 1 and 3 3alpha-hydroxysteroid dehydrogenase: Differential lability and tissue distribution. J Clin Endocrinol Metab 86:841-846, 2001
56. Dumont M, Luu-The V, Dupont E, Pelletier G, Labrie F: Characterization, expression, and immunohistochemical localization of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase in human skin. J Invest Dermatol 99:415-421, 1992
57. Eicheler W, Dreher M, Hoffmann R, Happle R, Aumüller G: Immunohistochemical evidence for differential distribution of 5α-reductase isozymes in human skin. Br J Dermatol 133:371-376, 1995
58. Eicheler W, Happle R, Hoffmann R: 5 Alpha-reductase activity in the human hair follicle concentrates in the dermal papilla. Arch Dermatol Res 290:126-132, 1998
59. Engelhardt D, Weber MM: Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 49:261-267, 1994
60. Evans BA, Griffiths K, Morton MS: Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 147:295-302, 1995
61. Falsetti L, Rosina B, de Fusco D: Serum levels of 3 alpha-androstanediol glucuronide in hirsute and non-hirsute women. Eur J Endocrinol 138:421-424, 1998
62. Farnsworth WE, Brown JR: Metabolism of testosterone by the human prostate. JAMA 183:436-439, 1963
63. Flamigni C, Collins WP, Koullapis EN, Craft I, Sommerville IF: Androgen metabolism in human skin. J Clin Endocrinol Metab 32:737-743, 1971
64. Fritsch M, Orfanos CE, Zouboulis ChC: Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol 116:793-800, 2001
65. Frye SV, Bramson HN, Hermann DJ, Lee FW, Sinhababu AK, Tian G: Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Pharm Biotechnol 11:393-422, 1998
66. Gallegos AJ, Berliner DL: Transformation and conjugation of dehydroepiandrosterone by human skin. J Clin Endocrinol Metab 27:1214-1218, 1967
67. Giagulli VA, Giorgino R, Vermeulen A: Is plasma 5 alpha-androstane 3 alpha, 17 beta-diol glucuronide a biochemical marker of hirsutism in women? J Steroid Biochem Mol Biol 39:55-61, 1991
68. Gilad S, Chayen R, Tordjman K, Kisch E, Stern N: Assessment of 5 alpha-reductase activity in hirsute women: Comparison of serum androstanediol glucuronide with urinary androsterone and aetiocholanolone excretion. Clin Endocrinol 40:459-464, 1994
69. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO: A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. Clin Pharmacol Ther 64:636-647, 1998
70. 14C in human skin. Biochemistry 7:24-32, 1968
71. Guarna A, Belle C, Machetti F, et al: 19-nor-10-azasteroids: A novel class of inhibitors for human steroid 5alpha-reductases 1 and 2. J Med Chem 40:1112-1129, 1997
72. Guarna A, Machetti F, Occhiato EG, et al: Benzo[c]quinolizin-3-ones: A novel class of potent and selective nonsteroidal inhibitors of human steroid 5alpha-reductase 1. J Med Chem 43:3718-3735, 2000
73. Hamilton JB: Male hormone is prerequisite and an incitant in common baldness. Am J Anat 71:451-480, 1942
74. Happle R, Hoffmann R: Absence of male-pattern baldness in men with X-linked recessive ichthyosis? A hypothesis to be challenged. Dermatology 198:231-232, 1999
75. Harada N: [A new aspect of the pharmacological and physiological significance of the aromatase/estrogen system]. [Japanese]. Nippon Yakurigaku Zasshi 112:51-58, 1998
76. Harada N: Aromatase and intracrinology of estrogen in hormone-dependent tumors. Oncology 57(Suppl. 2):7-16, 1999
77. Hartmann RW, Hector M, Haidar S, Ehmer PB, Reichert W, Jose J: Synthesis and evaluation of novel steroidal oxime inhibitors of P450 17 (17 alpha-hydroxylase/C17-20-lyase) and 5 alpha-reductase types 1 and 2. J Med Chem 43: 4266-4277, 2000
78. Hasebe K, Hara A, Nakayama T, Hayashibara M, Inoue Y, Sawada H: Inhibition of hepatic 17 beta- and 3 alpha-hydroxysteroid dehydrogenases by antiinflammatory drugs and nonsteroidal estrogens. Enzyme 37:109-114, 1987
79. Herrmann FH: [The genetics and molecular genetics of X-chromosomal recessive ichthyosis]. [German]. Dermatol Monatsschr 175:197-202, 1989
80. Herrmann FH, Wirth B, Wulff K, et al: Gene diagnosis in X-linked ichthyosis. Arch Dermatol Res 280:457-461, 1989
81. Hevert F: 17α-estradiol-ein moderner inhibitor der 5α-reductase. In: Plettenberg A, Meigel WN Moll I, (eds) Dermatologie an Der Schwelle Zum Neuen Jahrtausend. Aktueller Stand von Klinik und Forschung. Berlin: Springer-Verlag, 2000 pp 435-437
82. Hoffmann R, Happle R: Finasteride is the main inhibitor of 5 alpha-reductase activity in microdissected dermal papillae of human hair follicles. Arch Dermatol Res 291:100-103, 1999
83. Hoffmann R, Happle R: Current understanding of androgenetic alopecia: Part I: Etiopathogenesis. Eur J Dermatol 10:319-327, 2000
84. Hoffmann R, Rot A, Niiyama S, Billich A: Steroid sulfatase in the human hair follicle concentrations in the dermal papilla. J Invest Dermatol 117:1342-1348, 2001
85. Horton R: Dihydrotestosterone is a peripheral paracrine hormone. J Androl 13:23-27, 1992
86. Hughes SV, Robinson E, Bland R, Lewis HM, Stewart PM, Hewison M: 1,25-dihydroxyvitamin D3 regulates estrogen metabolism in cultured keratinocytes. Endocrinology 138:3711-3718, 1997
87. Igarashi S, Inami H, Hara H, Koutoku H, Oritani H, Mase T: A novel class of inhibitors for human and rat steroid 5alpha-reductases: Synthesis and biological evaluation of indoline and aniline derivatives. III. Chem Pharm Bull (Tokyo) 48:1689-1697, 2000
88. Imperato-McGinley J, Gautier T, Cai LQ, Yee B, Epstein J, Pochi P: The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 76:524-528, 1993
89. Inano H, Ohba H, Tamaoki B: Photochemical inactivation of human placental estradiol 17 beta-dehydrogenase in the presence of 2,3-butanedione. J Steroid Biochem 19:1617-1622, 1983
90. Itami S, Takayasu S: Activity of 17 beta-hydroxysteroid dehydrogenase in various tissues of human skin. Br J Dermatol. 105:693-699, 1981
91. Itami S, Takayasu S: Activity of 3 beta-hydroxysteroid dehydrogenase delta 4-5 isomerase in the human skin. Arch Dermatol Res 274:289-294, 1982
92. Itami S, Sonada T, Kurata S, Takayasu S: Mechanism of action of androgen in hair follicles. J Dermatol Sci 7(Suppl.):S98-S103, 1994
93. James VH, Few JD: Adrenocorticosteroids: Chemistry, synthesis and disturbances in disease. Clin Endocrinol Metab 14:867-892, 1985
94. Jenkins JS, Ash S: The metabolism of testosterone by human skin in disorders of hair growth. J Endocrinol 59:345-51, 1973
95. Joura EA, Geusau A, Schneider B, Soregi G, Huber JC: Serum 3alpha-androstanediol-glucuronide is decreased in nonhirsute women with acne vulgaris. Fertil Steril 66:1033-1035, 1996
96. Joura EA, Sator MO, Geusau A, Zeisler H, Söregi G, Huber JC: Die klinische wertigkeit von 3 alpha-androstanediol-glucuronid bei hilsuten frauen. Wien Klin Wochenschr 109:919-921, 1997 (In German)
97. Katashima M, Irino T, Shimojo F, et al: Pharmacokinetics and pharmacodynamics of FK143, a nonsteroidal inhibitor of steroid 5 alpha-reductase, in healthy volunteers. Clin Pharmacol Ther 63:354-366, 1998
98. Kaufman KD: Androgen metabolism as it affects hair growth in androgenetic alopecia. Dermatol Clin 14:697-711, 1996
99. Kaufman KD, Olsen EA, Whiting D, et al: Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 39:578-589, 1998
100. Kauschansky A, Shohat M, Frydman M, Rosler A, Greenbaum E, Sirota L: Syndrome of alopecia totalis and 17β-hydroxysteroid dehydrogenase deficiency. Am J Med Genet 76:28-31, 1998
101. Kim MH, Herrmann WL: In vitro metabolism of dehydroepiandrosterone sulfate in foreskin, abdominal skin and vaginal mucosa. J Clin Endocrinol Metab 28:187-191, 1968
102. Kirschner MA, Samojlik E, Szmal E: Clinical usefulness of plasma androstanediol glucuronide measurements in women with idiopathic hirsutism. J Clin Endocrinol Metab 65:597-601, 1987
103. 4-androstene-3, 17-dione by tissue homogenates. J Biol Chem 210:933-939, 1954
104. Krazeisen A, Breitling R, Imai K, Fritz S, Moller G, Adamski J: Determination of cDNA, gene structure and chromosomal localization of the novel human 17beta-hydroxysteroid dehydrogenase type 7(1). FEBS Lett 460:373-379, 1999
105. Krazeisen A, Breitling R, Moller G, Adamski J: Phytoestrogens inhibit human 17 beta-hydroxysteroid dehydrogenase type 5. Mol Cell Endocrinol 171:151-162, 2001
106. Labrie F: Intracrinology. Mol Cell Endocrinol 78:113-118, 1991
107. Labrie F, Simard J, Luu-The V, et al: Structure and tissue-specific expression of 3 beta-hydroxysteroid dehydrogenase/delta 5-delta 4 isomerase genes in human and rat classical and peripheral steroidogenic tissues. J Steroid Biochem Mol Biol 41:421-435, 1992
108. Labrie F, Belanger A, Simard J, Luu-The V, Labrie C: DHEA and peripheral androgen and estrogen formation: Intracrinology. Ann N Y Acad Sci 774:16-28, 1995
109. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, Bélanger A: The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 62: 148-158, 1997
110. Labrie F, Luu-The V, Lin SX, et al: Intracrinology: Role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 25:1-16, 2000a
111. Labrie F, Luu-The V, Labrie C, Pelletier G, El-Alfy M: Intracrinology and the skin. Hormone Res 54:213-229, 2000b
112. Lawate SS, Covey DF: Trifluoromethylacetylenic alcohols as affinity labels: Inactivation of estradiol dehydrogenase by a trifluoromethylacetylenic secoestradiol. J Med Chem 33:2319-2321, 1990
113. Le Bail JC, Laroche T, Marre-Fournier F, Habrioux G: Aromatase and 17beta-hydroxysteroid dehydrogenase inhibition by flavonoids. Cancer Lett 133:101-106, 1998
114. Le Bail JC, Champavier Y, Chulia AJ, Habrioux G: Effects of phytoestrogens on aromatase, 3beta and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells. Life Sci 66:1281-1291, 2000
115. Le Bail JC, Pouget C, Fagnere C, Basly JP, Chulia AJ, Habrioux G: Calcones are potent inhibitors of aromatase and 17beta-hydroxysteroid dehydrogenase activities. Life Sci 68:751-761, 2001
116. Legro RS, Carmina E, Stanczyk FZ, Gentzschein E, Lobo RA: Alterations in androgen conjugate levels in women and men with alopecia. Fertil Steril 62:744-750, 1994
117. Leshin M, Wilson JD: Inhibition of steroid 5 alpha-reductase from human skin fibroblasts by 17 beta-N,N-diethylcarbamoyl-4-methyl-4-aza-5 alpha-androstan-3-one. J Steroid Biochem 17:245-250, 1982
118. Levy MA, Brandt M, Sheedy KM, et al: Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. J Steroid Biochem Mol Biol 48:197-206, 1994
119. Li PK, Chu GH, Guo JP, Peters A, Selcer KW: Development of potent non-estrogenic estrone sulfatase inhibitors. Steroids 63:425-432, 1998
120. Li X, Chen C, Singh SM, Labrie F: The enzyme and inhibitors of 4-ene-3-oxosteroid 5α-oxidoreductase. Steroids 60:430-441, 1995
121. Liang T, Liao S: Inhibition of steroid 5α-reductase by specific aliphatic unsaturated fatty acids. Biochem J 285:557-562, 1992
122. Liang T, Liao S: Growth suppression of hamster flank organs by topical application of γ-linolenic acid and other fatty acid inhibitors of 5α-reductase. J Invest Dermatol 109:152-157, 1997
123. Liang T, Rasmusson GH, Brooks JR: Biochemical and biological studies with 4-azasteroidal 5α-reductase inhibitors. J Steroid Biochem 19:385-390, 1983
124. Liang T, Heiss CE, Cheung AH, Reynolds GF, Rasmusson GH: 4-azasteroidal 5 alpha-reductase inhibitors without affinity for the androgen receptor. J Biol Chem 259:734-739, 1984
125. Liao S, Hiipakka RA: Selective inhibition of steroid 5α-reductase isozymes by tea epicatechin-3-gallate and epigallocatechin-3-gallate. Biochem Biophys Res Commun 214:833-838, 1995
126. Liao S, Lin J, Dang MT, Zhang H, Kao Y-H, Fukuchi J, Hiipakka RA: Growth suppression of hamster flank organs by topical application of catechins, alizarin, curcumin, and myristoleic acid. Arch Dermatol Res 293:200-205, 2001
127. Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA, Penning TM: Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: Demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol 11:1971-1984, 1997
128. Lin H, Chien CH, Lin YL, Chen CF, Wang PS: Inhibition of testosterone secretion by S-petasin in rat testicular interstitial cells. Chin J Physiol 43:99-103, 2000
129. Lookingbill DP, Horton R, Demers LM, Egan N, Marks JG Jr, Santen RJ: Tissue production of androgens in women with acne. J Am Acad Dermatol 12:481-487, 1985
130. Lookingbill DP, Demers LM, Tigelaar RE, Shalita AR: Effect of isotretinoin on serum levels of precursor and peripherally derived androgens in patients with acne. Arch Dermatol 124:540-543, 1988a
131. Lookingbill DP, Egan N, Santen RJ, Demers LM: Correlation of serum 3 alpha-androstanediol glucuronide with acne and chest hair density in men. J Clin Endocrinol Metab 67:986-991, 1988b
132. Luu-The V: Analysis and characteristics of multiple types of human 17β-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 76:143-151, 2001
133. Luu-The V, Sugimoto Y, Puy L, Labrie Y, Solache IL, Singh M, Labrie F: Characterization, expression, and immunohistochemical localization of 5α-reductase in human skin. J Invest Dermatol 102:221-226, 1994
134. Luu-The V, Zhang Y, Poirier D, Labrie F: Characteristics of human types 1, 2 and 3 17 beta-hydroxysteroid dehydrogenase activities: Oxidation/reduction and inhibition. J Steroid Biochem Mol Biol 55:581-587, 1995
135. Mahesh VB, Brann DW: Regulation of the preovulatory gonadotropin surge by endogenous steroids. Steroids 63:616-629, 1998
136. Makela S, Poutanen M, Lehtimaki J, Kostian ML, Santti R, Vihko R: Estrogen-specific 17 beta-hydroxysteroid oxidoreductase type 1 (E.C. 1.1.1.62) as a possible target for the action of phytoestrogens. Proc Soc Exp Biol Med 208:51-59, 1995
137. Makela S, Poutanen M, Kostian ML, Lehtimaki N, Strauss L, Santti R, Vihko R: Inhibition of 17beta-hydroxysteroid oxidoreductase by flavonoids in breast and prostate cancer cells. Proc Soc Exp Biol Med 217:310-316, 1998
138. Matteri RK, Stanczyk FZ, Gentzschein EE, Delgado C, Lobo RA: Androgen sulfate and glucuronide conjugates in nonhirsute and hirsute women with polycystic ovarian syndrome. Am J Obstet Gynecol 161:1704-1709, 1989
139. Mauvais-Jarvis P, Kuttenn F, Mowszowicz I: Hirsutism. Monogr Endocrinol 19:1-116, 1981
140. McNulty AM, Audia JE, Bemis KG, Goode RL, Rocco VP, Neubauer BL: Kinetic analysis of LY320236: Competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5 alpha-reductase. J Steroid Biochem Mol Biol 72:13-21, 2000
141. Mendoza-Hernandez G, Lopez-Solache I, Diaz-Zagoya JC: Periodate-oxidized NADP+ is a powerful inhibitor of human placental estradiol-17 beta dehydrogenase. Biochem Biophys Res Commun 146:645-651, 1987
142. Menon GK, Feingold KR, Mosr AH, Brown BE, Elias PM: De novo sterologenesis in the skin. II. Regulation by cutaneous barrier requirements. J Lipid Res 26:418-427, 1985
143. Mestayer C, Berthaut I, Portois MC, Wright F, Kuttenn F, Mowszowicz I, Mauvais-Jarvis P: Predominant expression of 5 alpha-reductase type 1 in pubic skin from normal subjects and hirsute patients. J Clin Endocrinol Metabol 81:1989-1993, 1996
144. Milewich L, Shaw CB, Sontheimer RD: Steroid metabolism by epidermal keratinocytes. Ann N Y Acad Sci 548:66-89, 1988
145. Milewich L, Sontheimer RD, Herndon JH Jr: Steroid sulfatase activity in epidermis of acne-prone and non-acne-prone skin of patients with acne vulgaris. Arch Dermatol 126:1312-1314, 1990
146. Moger WH: Monodansylcadaverine inhibition of testicular 17-ketosteroid reductase. Can J Physiol Pharmacol 60:858-861, 1982
147. Montagna W: Phylogenetic significance of the skin of man. Arch Dermatol 88:1-9, 1963
148. Morita E, Katoh O, Shinoda S, Hiragun T, Tanaka T, Kameyoshi Y, Yamamoto S: A novel point mutation in the steroid sulfatase gene in X-linked ichthyosis. J Invest Dermatol 109:244-245, 1997
149. Murray M, Butler AM, Martini R: Inhibition of microsomal 17 beta-hydroxysteroid oxidoreduction activities in rat liver by all-trans-, 9-cis- and 13-cis-retinoic acid. Biochim Biophys Acta 1222:227-233, 1994
150. Napoli JL: 17beta-Hydroxysteroid dehydrogenase type 9 and other short-chain dehydrogenases/reductases that catalyze retinoid, 17beta- and 3alpha-hydroxysteroid metabolism. Mol Cell Endocrinol 171:103-109, 2001
151. New MI, Dupont B, Pang S, Pollack M, Levine LS: An update of congenital adrenal hyperplasia. Recent Prog Horm Res 37:105-181, 1981
152. Ngatcha BT, Luu-The V, Poirier D: Androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase. Bioorg Med Chem Lett 10:2533-2536, 2000
153. Niiyama S, Kojima K, Hamada T, Happle R, Hoffmann R: The novel drug CS-891 inhibits 5 alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol 10:593-595, 2000
154. Niiyama S, Happle R, Hoffmann R: The feasibility of quantitative analysis of androgen metabolism by use of single dermal papillae from human hair follicles. Exp Dermatol 10:124-127, 2001
155. Nnane IP, Long BJ, Ling YZ, Grigoryev DN, Brodie AM: Anti-tumor effects and pharmacokinetic profile of 17-(5′-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: An inhibitor of androgen synthesis. Br J Can 83:74-82, 2000
156. Nukui F: Effects of chlormadinone acetate and ethinylestradiol treatment on epididymal 5 alpha-reductase activities in patients with prostate cancer. Endocrinol J 44:127-132, 1997
157. Ohmura M, Hara A, Nakagawa M, Sawada H: Demonstration of 3 alpha(17 beta)-hydroxysteroid dehydrogenase distinct from 3 alpha-hydroxysteroid dehydrogenase in hamster liver. Biochem J 266:583-589, 1990
158. Pang S, Wang M, Jeffries S, Riddick L, Clark A, Estrada E: Normal and elevated 3 alpha-androstanediol glucuronide concentrations in women with various causes of hirsutism and its correlation with degree of hirsutism and androgen levels. J Clin Endocrinol Metab 75:243-248, 1992
159. Paulson RJ, Serafini PC, Catalino JA, Lobo RA: Measurement of 3 alpha, 17 beta-androstanediol glucuronide in serum and urine and the correlation with skin 5 alpha-reductase activity. Fertil Steril 46:222-226, 1986
160. Pawlowski J, Huizinga M, Penning TM: Isolation and partial characterization of a full-length cDNA clone for 3 alpha-hydroxysteroid dehydrogenase: A potential target enzyme for nonsteroidal anti-inflammatory drugs. Agents Actions 34:289-293, 1991
161. Pelletier G, Dumont E, Simard J, Luu-The V, Belanger A, Labrie F: Ontogeny and subcellular localization of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) in the human and rat adrenal, ovary and testis. J Steroid Biochem Mol Biol 43: 451-467, 1992
162. Pelletier G, Luu-The V, Tetu B, Labrie F: Immunocytochemical localization of type 5 17 beta-hydroxysteroid dehydrogenase in human reproductive tissues. J Histochem Cytochem 47:731-738, 1999
163. Penning TM: Molecular determinants of steroid recognition and catalysis in aldoketo reductases. Lessons from 3 alpha-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 69:211-225, 1999
164. Penning TM, Pawlowski JE, Schlegel BP, et al: Mammalian 3 alpha-hydroxysteroid dehydrogenases. Steroid 62:455-456, 1996
165. Penning TM, Pawlowski JE, Schlegel BP, et al: Mannalian 3 alpha-hydroxysteroid dehydrogenases. Steroids 62:455-456, 1997
166. Petrone A, Civitillo RM, Galante L, Giannotti F, D'Anto V, Rippa G, Tolino A: Usefulness of a 12-month treatment with finasteride in idiopathic and polycystic ovary syndrome-associated hirsutism. Clin Exp Obstet Gynecol 26:213-216, 1999
167. Pittaway DE: Inhibition of testosterone synthesis in the canine testis in vitro. Contraception 27:431-436, 1983
168. Poirier D, Dionne P, Auger S: A 6beta-(thiaheptanamide) derivative of estradiol as inhibitor of 17beta-hydroxysteroid dehydrogenase type 1. J Steroid Biochem Mol Biol 64:83-90, 1998
169. Pochi PE, Strauss JS: Endocrinologic control of the development and activity of the human sebaceous gland. J Invest Dermatol 62:191-201, 1974
170. Purohit A, Woo LW, Barrow D, Hejaz HA, Nicholson RI, Potter BV, Reed MJ: Non-steroidal and steroidal sulfamates: New drugs for cancer therapy. Mol Cell Endocrinol 171:129-135, 2001
171. Qin KN, Rosenfield RL: Expression of 17 beta-hydroxysteroid dehydrogenase type 5 in human ovary: A pilot study. J Soc Gynecol Invest 7:61-64, 2000
172. Ray A, Chatterjee S, Biswas NM: Study on the activities of testes and accessory sex glands after losulazine treatment in rats. Toxicol Lett 73:175-183, 1994
173. Rink JD, Simpson ER, Barnard JJ, Bulun SE: Cellular characterization of adipose tissue from various body sites of women. J Clin Endocrinol Metab 81:2443-2447, 1996
174. Rittmaster RS: Clinical relevance of testosterone and dihydrotestosterone metabolism in women. Am J Med 98:17S-21S, 1995
175. Rittmaster RS, Thompson DL: Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: The relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J Clin Endocrinol Metab 70:1096-1102, 1990
176. Russell DW, Wilson JD: Steroid 5 alpha-reductase: Two genes/two enzymes. Annu Rev Biochem 63:25-61, 1994
177. Saez JM, de Peretti E, Morera AM, David M, Bertrand J: Familial male pseudohermaphroditism and gynecomastia due to a testicular 17-ketosteroid reductase defect. Studies in vivo. J Clin Endocrinol Metab 32:604-610, 1971
178. Sakamoto K, Wakabayashi K: Inhibitory effect of glycyrrhetinic acid on testosterone production in rat gonads. Endocrinol Jap 35:333-342, 1988
179. di Salle E, Giudici D, Radice A, et al: PNU 157706, a novel dual type I and type II 5α-reductase inhibitor. J Steroid Biochem Mol Biol 64:179-186, 1998
180. Salman K, Spielvoge RL, Shulman LH, Miller JL, Vanderlinde RE, Rose LI: Serum androstanediol glucuronide in women with facial hirsutism. J Am Acad Dermatol 26:411-414, 1992
181. Sam KM, Auger S, Luu-The V, Poirier D: Steroidal spiro-gamma-lactones that inhibit 17 beta-hydroxysteroid dehydrogenase activity in human placental microsomes. J Med Chem 38:4518-4528, 1995
182. Sam KM, Labrie F, Poirier D: N-Butyl-N-methyl-11-(3′-hydroxy-21′,17′-carbolac-tone- 19′-nor-17′alpha-pregna-1′,3′,5′ (10′)-trien-7′alpha-yl)-undecanamide: An inhibitor of type 2 17beta-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity. Eur J Med Chem 35:217-225, 2000
183. Sato T, Sonada T, Itami S, Takayasu S: Predominance of type 1 5 alpha-reductase in apocrine sweat glands of patients with excessive or abnormal odour derived from apocrine gland (osmidrosis). Br J Dermatol 139:806-810, 1998
184. Sato T, Tadokoro T, Sonoda T, Asada Y, Itami S, Takayasu S: Minoxidil increases 17β-HSD and 5α-reductase activity of cultured human dermal papilla cells from balding scalp. J Dermatol Sci 19:123-125, 1999
185. Sawaya ME: Steroid chemistry and hormone controls during the hair follicle cycle. Ann N Y Acad Sci 642:376-383, 1991
186. Sawaya ME, Penneys NS: Immunohistochemical distribution of aromatase and 3 β-hydroxysteroid dehydrogenase in human hair follicle and sebaceous gland. J Cutan Pathol 19:309-314, 1992
187. Sawaya ME, Price VH: Different levels of 5 alpha-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 109:296-300, 1997
188. Sawaya ME, Honig LS, Garland LD, Hsia SL: Delta 5-3-beta-hydroxysteroid dehydrogenase activity in sebaceous glands of scalp in male-pattern baldness. J Invest Dermatol 91:101-105, 1988
189. Schlammadinger J, Meyer JC, Vajda I, Szabo G: X-linked recessive ichthyosis. Reinvestigation of a family first described in 1928. Dermatologica 175:217-223, 1987
190. Schneider JJ, Horstmann PM: Effects of incubating desoxycorticosterone with various rat tissues. J Biol Chem 191:327-338, 1951
191. Schwartz JI, Tanaka WK, Wang DZ, et al: MK-386, an inhibitor of 5 alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen. J Clin Endocrinol Metab 82:1373-1377, 1997
192. Serafini P, Ablan F, Lobo RA: 5 alpha-reductase activity in the genital skin of hirsute women. J Clin Endocrinol Metab 60:349-355, 1985
193. Serafini P, Lobo RA: Increased 5 alpha-reductase activity in idiopathic hirsutism. Fertil Steril 43:74-78, 1985
194. Shimizu K, Fukuda M, Kondo R, Sakai K: The 5 alpha-reductase inhibitory components from heartwood of Artocarpus incisus: Structure-activity investigations. Planta Med 66:16-19, 2000
195. Simard J, Durocher F, Mebarki F, et al: Molecular biology and genetics of 3 beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. J Endocrinol 150(Suppl.)189-S207, 1996
196. Simpson ER: Genetic mutations resulting in estrogen insufficiency in the male. Mol Cell Endocrinol 145:55-59, 1998
197. Simpson ER: Role of aromatase in sex steroid action. J Mol Endocrinol 25:149-156, 2000a
198. Simpson ER: Genetic mutations resulting in loss of aromatase activity in humans and mice. J Soc Gynecol Invest 7:18-S21, 2000b
199. Simpson ER, Zhao Y, Agarwal VR, et al: Aromatase expression in health and disease. Recent Prog Horm Res 52:185-213, 1997
200. Simpton NB, Cunliffe WJ, Hodgins MB: The relationship between the vitro activity of 3 beta-hydroxysteroid dehydrogenase delta 4-5 isomerase in human sebaceous glands and their secretory activity in vivo. J Invest Dermatol 81:139-144, 1983
201. Smythe CD, Greenall M, Kealey T: The activity of HMG-CoA reductase and acetyl-CoA carboxylase in human apocrine sweat glands, sebaceous glands, and hair follicles is regulated by phosphorylation and by exogenous cholesterol. J Invest Dermatol 111:139-148, 1998
202. Sonada T, Itami S, Kurata S, Takayasu S: Testosterone metabolism by cultured human beard outer root sheath cells in comparison with epidermal keratinocytes. J Dermatol Sci 6:214-218, 1993
203. Stauss JS, Pochi PE: Recent advances in androgen metabolism and their relation to the skin. Arch Dermatol 100:621-636, 1969
204. Strauss JS, Pochi PE, Downing DT: Acne: Perspectives. J Invest Dermatol 62:321-325, 1974
205. Stillman SC, Evans BA, Hughes IA: Androgen dependent stimulation of aromatase activity in genital skin fibroblasts from normals and patients with androgen insensitivity. Clin Endocrinol 35:533-538, 1991
206. Sudo K, Yoshida K, Akinaga Y, Nakayama R: 5alpha-reduction of an anti-androgen TSAA-291, 16beta-ethyl-17beta-hydroxy-4-estren-3-one, by nuclear 5alpha-reductase in rat prostates. Steroids 38:55-71, 1981
207. Sugawara T, Shimizu H, Hoshi N, Fujimoto Y, Nakajima A, Fujimoto S: PCR diagnosis of X-linked ichthyosis: Identification of a novel mutation (E560P) of the steroid sulfatase gene. Hum Mutat 15:296, 2000
208. Sultan C, Coupe M, Devillier C, Chavis C, Terraza A, Descomps B: Metabolism of dihydrotestosterone in cultured skin fibroblasts: Reduction to 5 alpha-androstane-3-alpha, 17 beta-diol. CR Seances Soc Biol Fil 177:83-92, 1983
209. Sundberg JP, Boggess D, Sundberg BA, Eilertsen K, Parimoo S, Filippi M, Stenn K: Asebia-2J (Scd1(ab2J)): A new allele and a model for scarring alopecia. Am J Pathol 156:2067-2075, 2000
210. Svenstrup B, Brunner N, Dombernowsky P, Nohr I, Micic S, Bennett P, Spang-Thomsen M: Comparison of the effect of cortisol on aromatase activity and androgen metabolism in two human fibroblast cell lines derived from the same individual. J Steroid Biochem 35:679-687, 1990
211. Takahashi O, Imai K, Watanabe K, et al: [The effect of sodium-4-[2-(2,3-dimethyl-4-[1-(4-isobutylphenyl)ethoxy]benzolamino)phenoxy] butyrate (ONO-3805) and antiandrogenic agents on the rat accessory sex organs]. Hinyokika Kiyo 38:305-310, 1992
212. Takami H, Nonaka H, Kishibayashi N, Ishii A, Kase H, Kumazawa T: Synthesis of tricyclic compounds as steroid 5 alpha-reductase inhibitors. Chem Pharm Bull (Tokyo) 48:552-555, 2000
213. Takashima I: Androgenetic alopecia: pathophysiological aspects in man and animals. In: Orfanos CE Happle R (eds). Hair and Hair Diseases. Berlin: Springer-Verlag, 1990 pp 467-484
214. Takezawa Y, Fukabori Y, Yamanaka H, Mieda M, Honma S, Kushitani M, Hamataki N: Effects of the new steroidal antiandrogen TZP-4238 on hormone-induced canine prostatic hyperplasia. Prostate 21:315-329, 1992
215. Tausk M: Practically applicable results of twenty years of research in endocrinology. Prog Drug Res 2:137-164, 1968
216. Taylor W: The metabolism of progesterone by animal tissues in vitro. I. Factors influencing the metabolism of progesterone by rat liver and the investigation of the products of metabolism. Biochem J 56:463-470, 1954
217. Thiboutot D, Harris G, Iles V, Cimis G, Gilliland K, Hagari S: Activity of the type 1 5 alpha-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol 105:209-214, 1995
218. Thiboutot D, Martin P, Volikos L, Gilliland K: Oxidative activity of the type 2 isozyme of 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD) predominates in human sebaceous glands. J Invest Dermatol 111:390-395, 1998
219. Thiboutot D, Gilliland K, Light J, Lookingbill D: Androgen metabolism in sebaceous glands from subjects with and without acne. Arch Dermatol 135:1041-1045, 1999
220. Thiboutot D, Bayne E, Thorne J, et al: Immunolocalization of 5 alpha-reductase isozymes in acne lesions and normal skin. Arch Dermaol 136:1125-1129, 2000
221. Thompson DL, Horton N, Rittmaster RS: Androsterone glucuronide is a marker of adrenal hyperandrogensim in hirsute women. Clin Endocrinol 32:283-292, 1990
222. Thornton MJ, Laing I, Hamada K, Messenger AG, Randall VA: Differences in testosterone metabolism by beard and scalp hair follicle dermal papilla cells. Clin Endocrinol 39:633-639, 1993
223. Toscano V, Balducci R, Bianchi P, et al: Two different pathogenetic mechanisms may play a role in acne and in hirsutism. Clin Endocrinol 39:551-556, 1993
224. Tremblay MR, Poirier D: Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: Chemical synthesis and biological evaluation. J Steroid Biochem Mol Biol 66:179-191, 1998
225. Tremblay MR, Auger S, Poirier D: Synthesis of 16-(bromoalkyl)-estradiols having inhibitory effect on human placental estradiol 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD type 1). Bioorg Med Chem 3:505-523, 1995
226. Tremblay MR, Luu-The V, Leblanc G, Noel P, Breton E, Labrie F, Poirier D: Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: Chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities. Bioorg Med Chem 7:1013-1023, 1999
227. Trueb RM.: Meyer JC: Male-pattern baldness in men with X-linked recessive ichthyosis. Dermatology 200:247-249, 2000
228. Tsai SC, Chen JJ, Chiao YC, et al: The role of cyclic AMP production, calcium channel activation and enzyme activities in the inhibition of testosterone secretion by amphetamine. Br J Pharmacol 122:949-955, 1997
229. Tsukada M, Schröder M, Roos TC, et al: 13- cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all- trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol 115: 321-327, 2000
230. Valdes-Flores M, Kofman-Alfaro SH, Vaca AL, Cuevas-Covarrubias SA: Deletion of exons 1-5 of the STS gene causing X-linked ichthyosis. J Invest Dermatol 116:456-458, 2001
231. Vermeulen A, Giagulli VA: Physiology of plasma androstanediol glucuronide. J Steroid Biochem Mol Biol 39:829-833, 1991
232. de Villez RL, Dunn J: Female androgenic alopecia. The 3 alpha, 17 beta-androstanediol glucuronide/sex hormone binding globulin ratio as a possible marker for female pattern baldness. Arch Dermatol 122:1011-1015, 1986
233. Virdis R, Saenger P, Senior B, New MI: Endocrine studies in a pubertal male pseudohermaphrodite with 17-ketosteroid reductase deficiency. Acta Endocrinol 87:212-224, 1978
234. Vogt C, Dericks-Tan JS, Kuhl H,Taubert HD: Is 3 alpha, 17 beta-androstanediol-glucuronide a diagnostic marker in women with androgenic manifestations? Gynecol Endocrinol 6:85-90, 1992
235. Williams ML, Rutherford SL, Feingold KR: Effects of cholesterol sulfate on lipid metabolism in cultured human keratinocytes and fibroblasts. J Lipid Res 28:955-967, 1987
236. Wilson JD, Walker JD: The conversion of testosterone to 5α-androstan-17β-ol-3-one (dihydrotestosterone) by skin slices of man. J Clin Invest 48:371-379, 1969
237. Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD: Measuring reversal of hair miniaturization in androgenetic alopecia by follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal women. J Invest Dermatol Symp Proc 4:282-284, 1999
238. Witt BR, Thorneycroft JH: Reproductive steroid hormones: Generation, degradation, reception, and action. Clin Obstet Gynecol 33:563-575, 1990
239. Woo LW, Howarth NM, Purohit A, Hejaz HA, Reed MJ, Potter BV: Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J Med Chem 41:1068-1083, 1998
240. Wotiz HH, Mescon H, Doppel H, Lemon HM: The in vitro metabolism of testosterone by human skin. J Invest Dermatol 26:113-120, 1956
241. Yamamoto T, Nozaki A, Shintani S, Ishikura S, Katagiri Y, Hara A: Structure-specific effects of thyroxine analogs on human liver 3 alpha-hydroxysteroid dehydrogenase. J Biochem 128:121-128, 2000
242. Zerhouni NA, Maes M, Sultan C, Rothwell S, Migeon CJ: Selective inhibition by secosteroids of 5 alpha-reductase activity in human sex skin fibroblasts. Steroids 33:277-285, 1979
243. Zettersten E, Man MQ, Sato J, et al: Recessive X-linked ichthyosis: Role of cholesterol-sulfate accumulation in the barrier abnormality. J Invest Dermatol 111: 784-790, 1998
244. Zhao Y, Mendelson CR, Simpson ER: Characterization of the sequences of the human CYP 19 (aromatase) gene that mediate regulation by glucocorticoids in adipose stromal cells and fetal hepatocytes. Mol Endocrinol 9:340-349, 1995
245. Zouboulis ChC: Human skin: An independent peripheral endocrine organ. Hormone Res 54:230-242, 2000a
246. Zouboulis ChC: Antiandrogene therapie-neue entwicklungen der systemischen und peripheren Inhibition. In: Plettenberg A, Meigel WN Moll I (eds). Dermatologie an Der Schwelle Zum Neuen Jahrtausend. Aktueller Stand von Klinik und Forschung. Berlin: Springer-Verlag, 2000b pp 427-431
247. Zouboulis ChC, Akamatsu H, Stephanek K, Orfanos CE: Androgens affect the activity of human sebocytes in culture in a manner dependent on the localization of the sebaceous glands and their effect is antagonized by spironolactone. Skin Pharmacol 7:33-40, 1994
248. Zouboulis ChC, Xia L, Akamatsu H, et al: The human sebocyte culture model provides new insights into development and management of seborrhoea and acne. Dermatology 196:21-31, 1998
249. Zouboulis ChC, Seltmann H, Neitzel H, Orfanos CE: Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). J Invest Dermatol 113:1011-1020, 1999
250. Zouboulis ChC, Seltmann H, Xia L, et al: Functions of the sebaceous gland and its role in acne, androgenetic alopecia and skin aging. J Invest Dermatol Symp Proc in press
251. Zwicker H, Rittmaster RS: Androsterone sulfate: Physiology and clinical significance in hirsute women. J Clin Endocrinol Metab 76:112-116, 1993